lymphoma

Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma.

Veteran Italian medical oncologist who leads oncology and haematology at Humanitas and has co-authored major trials in lymphoma, liver cancer and novel targeted drugs.

Basel haematologist-oncologist who co-led phase 2 trials of high-dose chemotherapy and autologous transplant in primary CNS lymphoma.

Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma.

Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma.

Lille haematologist and President of LYSA, the French-Belgian lymphoma cooperative group, who led the RELEVANCE trial of chemotherapy-free therapy in follicular lymphoma.

Swiss oncologist who presides over the board of the international study group that runs clinical trials in lymphomas arising outside the lymph nodes.

Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL.

Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.

Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years.

Medical oncologist who has led the Uganda Cancer Institute in Kampala, East Africa's principal cancer research and treatment centre.

Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma.

New York lymphoma specialist who led AUGMENT, the trial that established lenalidomide plus rituximab as a chemotherapy-free option for relapsed follicular and marginal zone lymphoma.

Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents.

Lymphoma specialist and Chief Executive Officer of the National Cancer Centre Singapore, the country's largest public cancer centre.

Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients.

Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma.

Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment.

Southampton lymphoma specialist who led the RATHL trial of PET-guided therapy in Hodgkin lymphoma and serves as NHS England's National Clinical Director for Cancer.

Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma.

Haematologist-oncologist and Deputy Medical Director at University Hospital Düsseldorf, known for drug-response profiling in lymphoma and leukaemia.

Led ZUMA-1, the trial that made axicabtagene ciloleucel the first CAR-T therapy approved for lymphoma.

Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries.

Led JULIET, which brought tisagenlecleucel, the first CAR-T, to adults with relapsed large B-cell lymphoma.

Led ECHELON-2, the first trial to improve survival in peripheral T-cell lymphoma, using brentuximab vedotin.

Discovered the MYD88 mutation that defines Waldenström macroglobulinaemia and led the trial that made ibrutinib its first approved drug.

Developed dose-adjusted EPOCH-R, the regimen that cures primary mediastinal B-cell lymphoma without radiotherapy.

Stanford dermatologist who led MAVORIC, the trial that established mogamulizumab for mycosis fungoides and Sézary syndrome after earlier treatment.

Lymphoma specialist and Vice President of Peking University Cancer Hospital.